title: 5-Hydroxyeicosatetraenoic acid and human parturition.
abstract: 5-Hydroxyeicosatetraenoic acid (5-HETE) is an arachidonic acid (AA) metabolite derived from the lipoxygenase pathway which is capable of inducing uterine contractions. The purpose of this study was to determine a). whether 5-HETE concentrations in amniotic fluid increase before or after the onset of labor and b). whether acetylsalicylic acid (ASA) could modulate the production of 5-HETE by human amnion cells. 5-HETE concentrations are increased in amniotic fluid before the onset of labor. Furthermore, ASA treatment as expected inhibited PGE2, but also significantly increased 5-HETE production by amnion cells. 5-HETE concentrations on average increased by greater than 2.5 fold (p < 0.001) in amniotic fluid prior to spontaneous labor when compared with samples obtained from the same patients earlier in gestation and therefore may be important in mechanisms regulating the onset of labor. ASA provokes an increase in 5-HETE biosynthesis by amnion cells: control media 2.60 +/- 1.5, ASA treatment alone 5.17 +/- 0.20, IL-1 beta alone 6.39 +/- 2.1, and ASA + IL-1 beta 8.95 +/- 1.2 (mean +/- SEM) picograms per microgram protein per 16 hours. These findings may explain in part why cyclooxygenase inhibitors are not always successful in treating women with preterm labor.
authors.affiliation: Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, USA.
authors.forename: S S
authors.initials: SS
authors.lastname: Edwin
authors.forename: R J
authors.initials: RJ
authors.lastname: Romero
authors.forename: H
authors.initials: H
authors.lastname: Munoz
authors.forename: D W
authors.initials: DW
authors.lastname: Branch
authors.forename: M D
authors.initials: MD
authors.lastname: Mitchell
mesh_terms: D000649:Amniocentesis; D000650:Amnion / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D000653:Amniotic Fluid / Q000378:metabolism*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D002478:Cells, Cultured; D015232:Dinoprostone / Q000096:biosynthesis; D005260:Female; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000032:analysis / Q000378:metabolism*; D007375:Interleukin-1 / Q000494:pharmacology; D007743:Labor, Obstetric / Q000187:drug effects / Q000378:metabolism*; D011247:Pregnancy
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006893:Hydroxyeicosatetraenoic Acids; D007375:Interleukin-1; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; D015232:Dinoprostone; D001241:Aspirin